Phase 2 Leukaemia Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been newly diagnosed with AML (acute myeloid leukemia) and have not yet received treatment for it
• Children and young people under 18 years old
• People who previously received hydroxyurea or a limited amount of a drug called cytarabine before their diagnosis, as long as the cytarabine was given for no more than 5 days at a low total dose
• People whose liver is working well enough, whose kidneys are filtering at an adequate level, and whose heart and oxygen levels are within acceptable ranges (confirm specific values with trial site)
• People who do not have an active infection, or whose infection symptoms have fully resolved for more than 3 days
• People who are generally able to carry out daily activities with little or no difficulty (measured using a standard scale called ECOG, score must be less than 2)
• People whose expected survival is greater than 12 weeks
• People (and/or their parent or legal guardian) who are willing to give written consent to participate

Who may not be able to join:

• People diagnosed with a specific type called acute megakaryocytic leukemia (AMKL)
• People diagnosed with a specific type called acute promyelocytic leukemia (APL)
• People whose AML developed as a result of previous cancer treatment, or who have AML that clearly developed from a blood condition called MDS
• People with a related blood or bone marrow disorder such as juvenile myelomonocytic leukemia (JMML)
• People whose AML developed from an inherited bone marrow failure condition, such as Fanconi anemia
• People whose AML is linked to Down syndrome
• People who are only able to receive temporary or one-off cancer treatments and cannot follow the full treatment plan required by the trial
• People who have another serious illness or mental health condition that could affect their safety, their ability to take part fully, or the reliability of the trial results (confirm with trial site, as individual cases are reviewed by the trial leadership)
• People who are severely malnourished, have a serious infection, have significant heart failure, or whose body is otherwise unable to tolerate chemotherapy
• People whose AML has come back after a previous remission (relapsed AML)
• People whose treating doctor decides, based on physical condition, personal circumstances, or other factors, that participation would not be appropriate

Important: Always verify eligibility with the trial site directly before applying.